Humana Inc. (NYSE:HUM) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, October 17th.
According to Zacks, “Humana is well poised to grow on its strong government business. Its top-line has been witnessing an uptrend from past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remains a positive. Following its strong second-quarter 2017 results, it raised its 2017 adjusted EPS guidance. The company has also seen the Zacks Consensus Estimate for the current year earnings being revised upward in last 30 days. Although the shares have performed in line with the industry in a year's time, its strong fundamentals are likely to help the stock in gaining momentum going forward. However, the company's individual commercial business has remained a drag over past few years. The company will release third quarter results on Nov 8, 2017.”
A number of other equities research analysts have also issued reports on HUM. UBS AG reiterated a “neutral” rating and issued a $237.00 target price (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. BidaskClub upgraded Humana from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $223.00 target price (up previously from $200.00) on shares of Humana in a research note on Thursday, August 3rd. Morgan Stanley increased their target price on Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research note on Thursday, August 17th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $257.00 price target on shares of Humana in a report on Friday, August 4th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $253.71.
Shares of Humana (NYSE:HUM) traded down $2.29 during trading on Tuesday, reaching $254.40. 455,770 shares of the company’s stock were exchanged, compared to its average volume of 962,866. The firm has a market capitalization of $37,096.12, a price-to-earnings ratio of 22.30, a P/E/G ratio of 1.66 and a beta of 0.91. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.65 and a quick ratio of 1.65. Humana has a 1 year low of $165.52 and a 1 year high of $264.56.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://baseballnewssource.com/markets/humana-inc-hum-cut-to-hold-at-zacks-investment-research/1721575.html.
In other news, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $251.88, for a total value of $3,022,560.00. Following the completion of the sale, the chief executive officer now owns 80,086 shares of the company’s stock, valued at $20,172,061.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP M Todoroff Christopher sold 22,935 shares of Humana stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,595 shares of company stock valued at $14,133,706. 0.80% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the company. WFG Advisors LP increased its stake in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the period. Acrospire Investment Management LLC bought a new position in shares of Humana in the second quarter worth about $120,000. Independent Portfolio Consultants Inc. increased its stake in Humana by 22.1% during the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after acquiring an additional 94 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Humana by 139.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after acquiring an additional 325 shares during the period. Finally, Fiduciary Trust Co. bought a new position in Humana during the second quarter valued at about $135,000. Institutional investors and hedge funds own 95.88% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with our FREE daily email newsletter.